This week in drug discovery (24-28 February)
News round-up for 23-28 February by DDW Senior Digital Content Editor Diana Spencer.
It’s been a mixed bag of news for gene therapies this week, ranging from huge successes in treating sight impairment, cystic fibrosis and hearing loss, to the quick sale of a previously successful gene therapy developer.
The top stories:
bluebird bio agrees to acquisition due to “financial challenges”
bluebird bio has entered into a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners in collaboration with a team of highly experienced biotech executives.
Gene therapy treats rare genetic sight impairment in the UK
Four young children have gained improvements in their vision following treatment with a new genetic medicine through Moorfields Eye Hospital and UCL Institute of Ophthalmology, with the support of MeiraGTx.
Inhaled gene therapy for cystic fibrosis enters the clinic
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and OXB have announced the start of LENTICLAIR 1, a Phase I/II trial of gene therapy BI 3720931.
Latest DB-OTO results confirm hearing improvements
Regeneron Pharmaceuticals has revealed updated data for the investigational gene therapy DB-OTO from the Phase I/II CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene.
